Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$17.31
+0.6%
$19.01
$10.21
$25.67
$4.11B0.432.58 million shs1.82 million shs
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$66.77
-0.2%
$63.16
$52.50
$77.00
$1.45B0.57279,070 shs265,690 shs
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
$2.86
+7.5%
$2.55
$1.11
$11.29
$51.83M1.57333,858 shs519,853 shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$87.27
-0.6%
$68.97
$40.61
$94.80
$5.59B2.26991,858 shs388,632 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
+0.88%-2.77%-3.75%-22.97%+25.00%
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
+0.84%+0.45%+1.32%-3.93%+3.35%
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
+1.07%-5.45%-0.19%+61.16%-75.23%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-0.01%-3.97%+41.33%+39.45%+76.33%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
3.7893 of 5 stars
3.71.00.00.02.42.53.1
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
3.8559 of 5 stars
2.51.00.03.33.23.31.3
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
2.2666 of 5 stars
3.51.00.00.02.71.70.6
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
3.1313 of 5 stars
2.51.00.04.32.20.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
3.33
Buy$27.6759.83% Upside
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
3.00
Buy$78.8818.13% Upside
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
3.00
Buy$18.00529.59% Upside
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
3.07
Buy$91.935.34% Upside

Current Analyst Ratings Breakdown

Latest ANIP, ADMA, ANVS, and RYTM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/18/2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$92.00 ➝ $105.00
7/10/2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
7/10/2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Buy$84.00
7/10/2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$76.00 ➝ $110.00
7/10/2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$73.00 ➝ $95.00
7/10/2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$91.00 ➝ $129.00
7/10/2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$97.00
7/9/2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$95.00
7/9/2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$72.00 ➝ $95.00
7/7/2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/7/2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform ➝ Outperform$88.00
(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$426.45M9.69$0.54 per share31.78$1.48 per share11.70
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$614.38M2.35$7.58 per share8.81$19.11 per share3.49
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/AN/AN/AN/A$0.67 per shareN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$130.13M42.67N/AN/A$0.35 per share249.34
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$197.67M$0.8530.7125.09N/A45.01%47.16%30.51%8/6/2025 (Estimated)
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
-$18.52M-$1.2714.9315.86N/A-3.12%21.35%7.52%8/5/2025 (Estimated)
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-$24.59M-$2.160.00N/AN/AN/A-300.56%-193.50%8/13/2025 (Estimated)
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$260.60M-$2.810.00N/AN/A-123.26%-739.62%-44.27%8/5/2025 (Estimated)

Latest ANIP, ADMA, ANVS, and RYTM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$0.14N/AN/AN/AN/AN/A
8/13/2025Q2 2025
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-$0.36N/AN/AN/AN/AN/A
8/5/2025Q2 2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$1.49N/AN/AN/A$187.18 millionN/A
8/5/2025Q2 2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.64N/AN/AN/A$43.72 millionN/A
5/13/2025Q1 2025
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-$0.47-$0.32+$0.15-$0.32N/AN/A
5/9/2025Q1 2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$1.37$1.70+$0.33$0.69$179.75 million$197.12 million
5/7/2025Q1 2025
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$0.16$0.14-$0.02$0.11$116.40 million$114.80 million
5/7/2025Q1 2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.69-$0.81-$0.12-$0.81$40.43 million$37.72 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
N/AN/AN/AN/AN/A
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
N/AN/AN/AN/AN/A
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/AN/AN/AN/AN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
0.22
6.58
3.36
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
1.46
2.66
1.98
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/A
10.68
10.68
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
3.30
3.13

Institutional Ownership

CompanyInstitutional Ownership
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
75.68%
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
76.05%
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
15.83%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
3.50%
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
11.10%
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
20.80%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
6.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
530238.73 million230.38 millionOptionable
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
60021.66 million19.26 millionOptionable
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
319.49 million15.43 millionOptionable
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
14063.62 million59.74 millionOptionable

Recent News About These Companies

Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $105.00
Rhythm Pharmaceuticals (NASDAQ:RYTM) Cut to "Sell" at Wall Street Zen
Analysts Set Expectations for RYTM Q4 Earnings
Q2 EPS Estimate for Rhythm Pharmaceuticals Lifted by Analyst

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA Biologics stock logo

ADMA Biologics NASDAQ:ADMA

$17.31 +0.11 (+0.64%)
Closing price 04:00 PM Eastern
Extended Trading
$17.15 -0.16 (-0.92%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ANI Pharmaceuticals stock logo

ANI Pharmaceuticals NASDAQ:ANIP

$66.77 -0.13 (-0.19%)
Closing price 04:00 PM Eastern
Extended Trading
$67.10 +0.33 (+0.49%)
As of 04:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Annovis Bio stock logo

Annovis Bio NYSE:ANVS

$2.86 +0.20 (+7.48%)
Closing price 03:59 PM Eastern
Extended Trading
$2.84 -0.02 (-0.66%)
As of 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Rhythm Pharmaceuticals stock logo

Rhythm Pharmaceuticals NASDAQ:RYTM

$87.27 -0.54 (-0.61%)
Closing price 04:00 PM Eastern
Extended Trading
$87.24 -0.02 (-0.03%)
As of 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.